# Pacira BioSciences (PCRX) — Earnings

PCRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/pcrx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.73 |
| EPS estimate | $0.65 |
| EPS surprise | +12.95% |
| Revenue surprise | +0.70% |
| Revenue | $192.4M |
| Revenue estimate | $191.1M |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1396814/000162828026052635/pcrx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/d9f5ba9b-d70c-d8ca-4cb6-ed9ec486ef53.html) |

Pacira reported Q2 2026 results on August 4, 2026. Earnings per share came in at $0.73, beating the $0.65 estimate by 12.95%. Revenue was $192.4 million, just above the $191.1 million consensus. Compared with Q2 2025, EPS was about 1% lower than $0.74, while revenue rose about 6% from $181.1 million.

Annual revenue rose from $666.9 million in 2022 to $726.4 million in 2025, and Q4 2025's $196.9 million is the highest quarter in the table. Earnings have been less even. Annual EPS went from $2.59 in 2022 to $2.92 in 2023 and $3.21 in 2024, then fell about 18% to $2.63 in 2025. The first half of 2026 adds up to $1.33, close to $1.36 a year earlier. Every quarter shown was profitable. Over the last 20 quarters, Pacira beat the EPS estimate 12 times. Its largest miss was Q2 2022, at 40.15%, and the latest was Q4 2025, at 37.01%.

Pacira reported Q3 results between November 2 and November 6 in each of the past five years. That points to early November 2026 for the next report. It will show whether revenue growth continues and whether EPS moves back above year-earlier levels.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | $0.65 | $0.73 | 12.95% | $191.1M | $192.4M |
| Q1 2026 | Apr 30, 2026 | $0.55 | $0.60 | 9.57% | $171.8M | $177.4M |
| Q4 2025 | Feb 26, 2026 | $0.90 | $0.57 | -37.01% | $200.3M | $196.9M |
| Q3 2025 | Nov 6, 2025 | $0.68 | $0.70 | 3.32% | $181.1M | $179.5M |
| Q2 2025 | Aug 5, 2025 | $0.71 | $0.74 | 4.23% | $183.1M | $181.1M |
| Q1 2025 | May 8, 2025 | $0.60 | $0.62 | 3.94% | $176.0M | $168.9M |
| Q4 2024 | Feb 27, 2025 | $0.84 | $0.91 | 8.94% | $184.7M | $187.3M |
| Q3 2024 | Nov 6, 2024 | $0.70 | $0.79 | 12.14% | $169.5M | $168.6M |
| Q2 2024 | Jul 30, 2024 | $0.70 | $0.89 | 27.34% | $173.7M | $178.0M |
| Q1 2024 | May 7, 2024 | $0.62 | $0.62 | -0.02% | $165.3M | $167.1M |
| Q4 2023 | Feb 29, 2024 | $0.88 | $0.89 | 0.76% | $180.6M | $181.2M |
| Q3 2023 | Nov 2, 2023 | $0.78 | $0.72 | -7.78% | $172.9M | $163.9M |
| Q2 2023 | Aug 2, 2023 | $0.76 | $0.78 | 2.81% | $174.9M | $169.5M |
| Q1 2023 | May 3, 2023 | $0.62 | $0.53 | -14.10% | $159.2M | $160.3M |
| Q4 2022 | Feb 28, 2023 | $0.83 | $0.80 | -3.56% | $171.9M | $172.0M |
| Q3 2022 | Nov 3, 2022 | $0.77 | $0.64 | -16.51% | $168.3M | $167.5M |
| Q2 2022 | Aug 3, 2022 | $0.85 | $0.51 | -40.15% | $170.6M | $169.4M |
| Q1 2022 | May 4, 2022 | $0.83 | $0.64 | -23.06% | $159.7M | $158.0M |
| Q4 2021 | Feb 24, 2022 | $0.90 | $0.97 | 7.42% | $156.3M | $159.2M |
| Q3 2021 | Nov 3, 2021 | $0.65 | $0.72 | 10.77% | $129.4M | $127.7M |

## Frequently Asked Questions

### When did Pacira BioSciences (PCRX) last report earnings?

Pacira BioSciences last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did PCRX beat earnings estimates?

Yes. Pacira BioSciences reported EPS of $0.73 for Q2 2026 against a $0.65 estimate — a 12.95% beat.

### How much revenue did PCRX report last quarter?

Pacira BioSciences reported $192.4M in revenue for Q2 2026, against a consensus estimate of $191.1M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).